JP2010514751A - オレキシン受容体拮抗薬としての２−アザ−ビシクロ［３．１．０］ヘキサン誘導体 - Google Patents

オレキシン受容体拮抗薬としての２−アザ−ビシクロ［３．１．０］ヘキサン誘導体 Download PDF

Info

Publication number
JP2010514751A
JP2010514751A JP2009543566A JP2009543566A JP2010514751A JP 2010514751 A JP2010514751 A JP 2010514751A JP 2009543566 A JP2009543566 A JP 2009543566A JP 2009543566 A JP2009543566 A JP 2009543566A JP 2010514751 A JP2010514751 A JP 2010514751A
Authority
JP
Japan
Prior art keywords
thiazole
aza
bicyclo
methyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009543566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514751A5 (esLanguage
Inventor
アイサオウイ ハメッド
ボス クリストフ
グード マーカス
コバースタイン ラルフ
セィファーレン ティエリー
トラッシェル ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of JP2010514751A publication Critical patent/JP2010514751A/ja
Publication of JP2010514751A5 publication Critical patent/JP2010514751A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
JP2009543566A 2006-12-28 2007-12-28 オレキシン受容体拮抗薬としての２−アザ−ビシクロ［３．１．０］ヘキサン誘導体 Pending JP2010514751A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2006055042 2006-12-28
PCT/IB2007/055326 WO2008081399A2 (en) 2006-12-28 2007-12-28 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists

Publications (2)

Publication Number Publication Date
JP2010514751A true JP2010514751A (ja) 2010-05-06
JP2010514751A5 JP2010514751A5 (esLanguage) 2011-02-17

Family

ID=39343649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543566A Pending JP2010514751A (ja) 2006-12-28 2007-12-28 オレキシン受容体拮抗薬としての２−アザ−ビシクロ［３．１．０］ヘキサン誘導体

Country Status (28)

Country Link
US (1) US8288435B2 (esLanguage)
EP (1) EP2094690B1 (esLanguage)
JP (1) JP2010514751A (esLanguage)
KR (1) KR20090094168A (esLanguage)
CN (1) CN101568536B (esLanguage)
AR (1) AR064561A1 (esLanguage)
AT (1) ATE505467T1 (esLanguage)
AU (1) AU2007340944B2 (esLanguage)
BR (1) BRPI0720876A2 (esLanguage)
CA (1) CA2669821A1 (esLanguage)
CL (1) CL2007003827A1 (esLanguage)
CY (1) CY1111705T1 (esLanguage)
DE (1) DE602007013937D1 (esLanguage)
DK (1) DK2094690T3 (esLanguage)
ES (1) ES2364297T3 (esLanguage)
HR (1) HRP20110509T1 (esLanguage)
MA (1) MA31000B1 (esLanguage)
MX (1) MX2009006860A (esLanguage)
MY (1) MY157344A (esLanguage)
NO (1) NO20092762L (esLanguage)
NZ (1) NZ578642A (esLanguage)
PL (1) PL2094690T3 (esLanguage)
PT (1) PT2094690E (esLanguage)
RU (1) RU2460732C2 (esLanguage)
SI (1) SI2094690T1 (esLanguage)
TW (1) TW200833328A (esLanguage)
WO (1) WO2008081399A2 (esLanguage)
ZA (1) ZA200905229B (esLanguage)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504957A (ja) * 2006-09-29 2010-02-18 アクテリオン ファーマシューティカルズ リミテッド ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体
JP2015502385A (ja) * 2011-12-21 2015-01-22 ロッタファーム・バイオテック・ソチエタ・ア・レスポンサビリタ・リミタータＲＯＴＴＡＰＨＡＲＭ ＢＩＯＴＥＣＨ Ｓ．ｒ．ｌ． 化学化合物
JP2015510909A (ja) * 2012-03-19 2015-04-13 ロッタファーム・バイオテック・ソチエタ・ア・レスポンサビリタ・リミタータＲＯＴＴＡＰＨＡＲＭ ＢＩＯＴＥＣＨ Ｓ．ｒ．ｌ． 化合物
JP2015522622A (ja) * 2012-07-18 2015-08-06 モラスキ，ギャレット ５，５−ヘテロ芳香族抗感染症化合物
JP2024504854A (ja) * 2021-02-02 2024-02-01 メッドシャイン ディスカバリー インコーポレイテッド テトラヒドロピロロ環化合物及びその使用

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133901B2 (en) 2006-12-01 2012-03-13 Actelion Pharmaceuticals Ltd. 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors
CL2008000836A1 (es) * 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
JP2010540429A (ja) * 2007-09-24 2010-12-24 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類
WO2009104155A1 (en) * 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives
WO2009133522A1 (en) * 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
WO2010044054A1 (en) * 2008-10-14 2010-04-22 Actelion Pharmaceuticals Ltd Phenethylamide derivatives and their heterocyclic analogues
EP2275421A1 (en) * 2009-07-15 2011-01-19 Rottapharm S.p.A. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
DK2519514T3 (en) * 2009-12-29 2015-11-16 Suven Life Sciences Ltd Neuronal nicotinic alpha4beta2-acetylcholine receptor ligands
US8268848B2 (en) * 2010-09-22 2012-09-18 Eisai R&D Management Co., Ltd. Cyclopropane compound
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
BR112014019426A8 (pt) 2012-02-07 2017-07-11 Eolas Therapeutics Inc Prolinas/ piperidinas substituídas como antagonistas do receptor de orexina
TWI510481B (zh) * 2012-06-04 2015-12-01 Actelion Pharmaceuticals Ltd 苯并咪唑脯胺酸衍生物
MX2015004638A (es) 2012-10-10 2015-07-14 Actelion Pharmaceuticals Ltd Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-) aril]-[2-meta bi-(hetero-) aril)-pirrolidin-1-il]-metanona.
JP2016510810A (ja) 2013-03-12 2016-04-11 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
HUE035731T2 (hu) 2013-12-03 2018-05-28 Idorsia Pharmaceuticals Ltd (S)-(2-(6-klór-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2- (2H-l,2,3-triazol-2-il)fenil)metanon kristályos formája és alkalmazása orexin receptor antagonistaként
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
LT3077391T (lt) 2013-12-04 2018-10-25 Idorsia Pharmaceuticals Ltd Benzimidazolo prolino darinių panaudojimas
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
AR101558A1 (es) 2014-08-13 2016-12-28 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores del receptor de orexina
KR102455043B1 (ko) 2014-09-11 2022-10-13 얀센 파마슈티카 엔.브이. 치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도
CN107810006B (zh) 2014-10-23 2021-03-30 卫材R&D管理有限公司 用于治疗失眠的组合物
CN106588900A (zh) * 2015-10-20 2017-04-26 北京康辰医药科技有限公司 一种苯并双环化合物或其药学上可接受的盐、药物组合物及其应用
AU2017217931B2 (en) 2016-02-12 2020-10-22 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
KR20180115743A (ko) * 2016-02-26 2018-10-23 지앙수 헨그루이 메디슨 컴퍼니 리미티드 신규 독소, 및 이의 중간체를 제조하는 방법
EP3454857A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
CN110612291B (zh) 2017-05-03 2024-02-13 爱杜西亚药品有限公司 2-([1,2,3]三唑-2-基)-苯甲酸衍生物的制备
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
MX2023001818A (es) 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
AU2021360172A1 (en) 2020-10-13 2023-03-30 Boehringer Ingelheim International Gmbh Process of reworking
WO2023218023A1 (en) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051368A1 (en) * 2001-12-19 2003-06-26 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
JP2004503537A (ja) * 2000-06-16 2004-02-05 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとして使用するためのピペリジン
WO2004041816A1 (en) * 2002-11-06 2004-05-21 Glaxo Group Limited Azacyclic compounds as orexin receptor antagonist
WO2004041791A1 (en) * 2002-11-06 2004-05-21 Glaxo Group Limited N-aryl acetyl cyclic amine derivatives as orexin antagonists
WO2004085403A1 (en) * 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
JP2004533440A (ja) * 2001-05-05 2004-11-04 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｎ−アロイルサイクリックアミン
WO2004096780A1 (en) * 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Quinoxalinone-3- one derivatives as orexin receptor antagonists
JP2004534026A (ja) * 2001-05-05 2004-11-11 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとしてのｎ−アロイルサイクリックアミン誘導体
JP2005501026A (ja) * 2001-06-28 2005-01-13 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 化合物
JP2005501027A (ja) * 2001-06-28 2005-01-13 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとしてのｎ−アロイル環状アミン誘導体
JP2005505603A (ja) * 2001-10-11 2005-02-24 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとしてのｎ−アロイルピペラジン誘導体
JP2005513011A (ja) * 2001-11-10 2005-05-12 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー ピペラジンビス−アミド誘導体およびオレキシン受容体のアンタゴニストとしてのその使用
WO2005118548A1 (en) * 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
JP2006504695A (ja) * 2002-09-18 2006-02-09 グラクソ　グループ　リミテッド オレキシン受容体アンタゴニストとしてのｎ−アロイル環状アミン
JP2010504957A (ja) * 2006-09-29 2010-02-18 アクテリオン ファーマシューティカルズ リミテッド ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621126A5 (esLanguage) 1974-02-07 1981-01-15 Plantex Ltd
AU2381995A (en) 1994-04-29 1995-11-29 Pharmacia & Upjohn Company Methanol derivatives for treatment of retroviral infections especially hiv infections
JP2004533989A (ja) 2000-11-20 2004-11-11 サイオス インコーポレイテッド ｐ３８キナーゼのピペリジン／ピペラジン型阻害剤
DE60108420T2 (de) 2000-11-28 2005-12-22 Smithkline Beecham P.L.C., Brentford Morpholinderivate als antagonisten an orexinrezeptoren
GB0111341D0 (en) 2001-05-10 2001-07-04 Bp Chem Int Ltd Novel polymerisation catalysts
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
US7994336B2 (en) * 2006-08-15 2011-08-09 Actelion Pharmaceuticals Ltd. Azetidine compounds as orexin receptor antagonists
US8133901B2 (en) * 2006-12-01 2012-03-13 Actelion Pharmaceuticals Ltd. 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors
CL2008000836A1 (es) * 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
US20100222328A1 (en) * 2007-05-14 2010-09-02 Hamed Aissaoui 2-cyclopropyl-thiazole derivatives
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
CN101679366B (zh) 2007-05-23 2013-08-07 默沙东公司 吡啶基哌啶食欲素受体拮抗剂
AU2008272449A1 (en) 2007-07-03 2009-01-08 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.3.0]octane compounds
AR067665A1 (es) 2007-07-27 2009-10-21 Actelion Pharmaceuticals Ltd Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
NZ583487A (en) * 2007-07-27 2011-09-30 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
JP2010540429A (ja) * 2007-09-24 2010-12-24 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類
WO2009104155A1 (en) * 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives
WO2009133522A1 (en) * 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
TW200940822A (en) * 2009-05-07 2009-10-01 Wan Chi Steel Ind Co Ltd Water wheel mechanism with sun-and-planet type blade

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004503537A (ja) * 2000-06-16 2004-02-05 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとして使用するためのピペリジン
JP2004533440A (ja) * 2001-05-05 2004-11-04 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｎ−アロイルサイクリックアミン
JP2004534026A (ja) * 2001-05-05 2004-11-11 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとしてのｎ−アロイルサイクリックアミン誘導体
JP2005501027A (ja) * 2001-06-28 2005-01-13 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとしてのｎ−アロイル環状アミン誘導体
JP2005501026A (ja) * 2001-06-28 2005-01-13 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 化合物
JP2005505603A (ja) * 2001-10-11 2005-02-24 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとしてのｎ−アロイルピペラジン誘導体
JP2005513011A (ja) * 2001-11-10 2005-05-12 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー ピペラジンビス−アミド誘導体およびオレキシン受容体のアンタゴニストとしてのその使用
WO2003051368A1 (en) * 2001-12-19 2003-06-26 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
JP2006504695A (ja) * 2002-09-18 2006-02-09 グラクソ　グループ　リミテッド オレキシン受容体アンタゴニストとしてのｎ−アロイル環状アミン
WO2004041791A1 (en) * 2002-11-06 2004-05-21 Glaxo Group Limited N-aryl acetyl cyclic amine derivatives as orexin antagonists
WO2004041816A1 (en) * 2002-11-06 2004-05-21 Glaxo Group Limited Azacyclic compounds as orexin receptor antagonist
WO2004085403A1 (en) * 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
WO2004096780A1 (en) * 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Quinoxalinone-3- one derivatives as orexin receptor antagonists
WO2005118548A1 (en) * 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
JP2010504957A (ja) * 2006-09-29 2010-02-18 アクテリオン ファーマシューティカルズ リミテッド ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504957A (ja) * 2006-09-29 2010-02-18 アクテリオン ファーマシューティカルズ リミテッド ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体
JP2015502385A (ja) * 2011-12-21 2015-01-22 ロッタファーム・バイオテック・ソチエタ・ア・レスポンサビリタ・リミタータＲＯＴＴＡＰＨＡＲＭ ＢＩＯＴＥＣＨ Ｓ．ｒ．ｌ． 化学化合物
JP2015510909A (ja) * 2012-03-19 2015-04-13 ロッタファーム・バイオテック・ソチエタ・ア・レスポンサビリタ・リミタータＲＯＴＴＡＰＨＡＲＭ ＢＩＯＴＥＣＨ Ｓ．ｒ．ｌ． 化合物
JP2015522622A (ja) * 2012-07-18 2015-08-06 モラスキ，ギャレット ５，５−ヘテロ芳香族抗感染症化合物
JP2024504854A (ja) * 2021-02-02 2024-02-01 メッドシャイン ディスカバリー インコーポレイテッド テトラヒドロピロロ環化合物及びその使用
JP7681113B2 (ja) 2021-02-02 2025-05-21 メッドシャイン ディスカバリー インコーポレイテッド テトラヒドロピロロ環化合物及びその使用

Also Published As

Publication number Publication date
CL2007003827A1 (es) 2008-09-26
CN101568536B (zh) 2011-12-28
WO2008081399A2 (en) 2008-07-10
RU2460732C2 (ru) 2012-09-10
ZA200905229B (en) 2010-10-27
MX2009006860A (es) 2009-07-07
DK2094690T3 (da) 2011-07-18
TW200833328A (en) 2008-08-16
CA2669821A1 (en) 2008-07-10
MA31000B1 (fr) 2009-12-01
RU2009128739A (ru) 2011-02-10
MY157344A (en) 2016-05-31
AU2007340944A1 (en) 2008-07-10
AR064561A1 (es) 2009-04-08
AU2007340944B2 (en) 2013-04-18
US20110124636A1 (en) 2011-05-26
NO20092762L (no) 2009-07-27
HK1136554A1 (en) 2010-07-02
WO2008081399A3 (en) 2008-08-28
SI2094690T1 (sl) 2011-07-29
DE602007013937D1 (de) 2011-05-26
KR20090094168A (ko) 2009-09-03
NZ578642A (en) 2012-01-12
EP2094690B1 (en) 2011-04-13
PL2094690T3 (pl) 2011-09-30
CY1111705T1 (el) 2015-10-07
EP2094690A2 (en) 2009-09-02
CN101568536A (zh) 2009-10-28
US8288435B2 (en) 2012-10-16
PT2094690E (pt) 2011-07-08
HRP20110509T1 (hr) 2011-08-31
ATE505467T1 (de) 2011-04-15
BRPI0720876A2 (pt) 2014-03-04
ES2364297T3 (es) 2011-08-30

Similar Documents

Publication Publication Date Title
JP2010514751A (ja) オレキシン受容体拮抗薬としての２−アザ−ビシクロ［３．１．０］ヘキサン誘導体
US8236801B2 (en) 2-aza-bicyclo[2.2.1]heptane derivatives
EP2185512B1 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
US8063099B2 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
EP2079690B1 (en) 3-aza-bicyclo[3.1.0]hexane derivatives
US8106215B2 (en) 3-aza-bicyclo[3.3.0]octane compounds
JP2010534647A (ja) ２−アザ−ビシクロ［３．３．０］オクタン誘導体
CN101711247A (zh) 2-环丙基-噻唑衍生物
HK1136554B (en) 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100217

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100217

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130626